Transition Bio provides condensate technology for drug discovery and diagnostics. The company focuses on the discovery, analysis, and modulation of biological condensates, propelled by a differentiated technological capability that generates expansive drug development opportunities in a hypothesis-free manner.
MindRight Health's mission is to advance health equity by making mental health care radically accessible and inclusive of communities of color and low-income families. MindRight partners with healthcare payers and providers to offer culturally-responsive mental health coaching over a text message. MindRight's members receive a personal team of coaches who proactively support them 7 days/week, 365 days/year. Through its service, MindRight is creating a continuum of support that does not generally exist for youth. For communities who do not traditionally engage in clinical services due to high stigma and lack of access, MindRight serves as an ongoing source of culturally responsive, nonclinical support. MindRight provides its partners with real-time data on community mental health needs to predict and prevent mental health crises in the communities.
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.
Aspen Neuroscience is a development stage and private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. It is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical needs, beginning with autologous neuron replacement for both sporadic and genetic forms of Parkinson's disease (PD) and extending across the brain and affected organs.
Founded in 2021, Cylinder delivers personalized, clinician-backed care to those suffering from digestive issues through its virtual health platform and has helped nearly 100K members to date. Cylinder's platform offers dynamically updated content and care plans designed to improve engagement and outcomes. Members enjoy access to a dedicated care team nationwide, including health coaches, registered dietitians, and GI doctors. Cylinder’s vision is to create a world where people receive convenient, personalized, and affordable access to the quality digestive health care they need to improve their overall health. Trusted by businesses including Texas A&M University, US Foods, and more, Cylinder showcases up to 5:1 ROI and an average of 13% employee engagement. Learn more at cylinderhealth.com.
Synapticure provides neurodegenerative disease patients with disease specialist and wrap around care, no matter where you live in the US. Founded by patients, we support Dementia, Parkinson's, ALS and more with everyone from on-demand disease-specific neurologists to SLT to 24/7 care coordination and support.
64x Bio builds a platform that increases the speed and scale of mammalian cell line discovery. The company uses a throughput discovery and screening platform and an integrated computational design loop, they develop new ways of generating highly optimized and otherwise unattainable cell lines for the manufacturing of viral vectors, with a specific focus on those used for cell and gene therapies.
PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and helped lead the world's largest open-science drug discovery effort; COVID Moonshot.
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics. The company is pioneering a powerful protein engineering-focused approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Their technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets.
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bio leverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Bayesian Health is an adaptive AI platform that offers health systems through clinical AI. The company's adaptive AI is intended to integrate with a hospital's EMR, where it provides actionable early detection flags and key insights displayed on the patient list and/or linked with paging, phone, or other escalation pathways to alert the appropriate clinician. An evidence-based AI/machine learning platform can leverage health systems' significant investment in the EMR as a foundation for patient data and help frontline healthcare providers increase capacity.
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from living organisms. By developing a comprehensive database of chemical biodiversity, Enveda aims to accelerate the discovery of new medicines.
Sempre Health is bringing dynamic pricing to healthcare. This allows patients to afford care for longer, which directly improves clinical outcomes / quality measures while reducing utilization / cost. Patients receive texts like, “If you fill your prescription today, you’ll pay $10. If you wait until next week, this could go back up to $30.” We parse millions of prescription records to identify unique patient behaviors. We use this data to predict and seamlessly deliver the right price for the right patient to every pharmacy in the country. At the same time, we’re generating the first ever real-world dataset on patient price sensitivities and cost behaviors.
Wren Therapeutics is a biopharmaceutical company based in Cambridge UK, focused on drug discovery and development for protein misfolding diseases, which include Alzheimer’s and Parkinson’s diseases, type-2 diabetes, and many rare forms of amyloidosis. Wren’s proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. Wren is using this platform to develop small molecule therapeutics for multiple protein misfolding diseases, including major neurological and rare disorders.
Sitka is a customizable video software platform that connects primary care providers to the virtual specialty provider network. By upskilling primary care providers, collapsing the care cycle, and enabling patient inclusion, Sitka is transforming specialty care in the US. Founded by healthcare experts in medicine, technology, policy, and product, Sitka’s mission is to foster informed, effective and trusted care delivery for all patients by every provider. The company is backed by investors including Venrock, Optum Ventures, First Round, Rock Health, Homebrew, Lifeforce Capital, and Box Group. It was established in San Francisco, California in 2018 by Kelsey Mellard, Shaun Lindsay, and Sohrab Gollogly.
Transition Bio provides condensate technology for drug discovery and diagnostics. The company focuses on the discovery, analysis, and modulation of biological condensates, propelled by a differentiated technological capability that generates expansive drug development opportunities in a hypothesis-free manner.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.
Sonoma Pharmaceuticals is a global healthcare company that designs, manufactures and markets prescription and non-prescription products in 33 countries. The company’s products, over 100 SKUs commercialized worldwide, are used to treat patients in advanced wound management, dermatology, women’s health and animal health; addressing the unmet medical needs of these markets—while raising the standard of patient care and lowering overall healthcare costs.
Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.
Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diverse macrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial.
Wren Therapeutics is a biopharmaceutical company based in Cambridge UK, focused on drug discovery and development for protein misfolding diseases, which include Alzheimer’s and Parkinson’s diseases, type-2 diabetes, and many rare forms of amyloidosis. Wren’s proprietary technology platform is built on new and fundamental understanding of the origins of these diseases and is based on decades of scientific research at the University of Cambridge and Lund University. Wren is using this platform to develop small molecule therapeutics for multiple protein misfolding diseases, including major neurological and rare disorders.
Cricket Health is a specialty kidney care provider of integrated nephrology and dialysis care for people with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Cricket Health delivers world-class, technology-enabled multidisciplinary care both in-person and virtually to achieve the best outcomes possible for patients and the best value for partners, keeping patients healthy and out of the hospital, accelerating access to transplant, and increasing home dialysis adoption. We are committed to aligning the success of our company with those of our partners and the patients whom we serve. Learn more at www.crickethealth.com and follow us @crickethealth
Sempre Health is bringing dynamic pricing to healthcare. This allows patients to afford care for longer, which directly improves clinical outcomes / quality measures while reducing utilization / cost. Patients receive texts like, “If you fill your prescription today, you’ll pay $10. If you wait until next week, this could go back up to $30.” We parse millions of prescription records to identify unique patient behaviors. We use this data to predict and seamlessly deliver the right price for the right patient to every pharmacy in the country. At the same time, we’re generating the first ever real-world dataset on patient price sensitivities and cost behaviors.
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.
Sitka is a customizable video software platform that connects primary care providers to the virtual specialty provider network. By upskilling primary care providers, collapsing the care cycle, and enabling patient inclusion, Sitka is transforming specialty care in the US. Founded by healthcare experts in medicine, technology, policy, and product, Sitka’s mission is to foster informed, effective and trusted care delivery for all patients by every provider. The company is backed by investors including Venrock, Optum Ventures, First Round, Rock Health, Homebrew, Lifeforce Capital, and Box Group. It was established in San Francisco, California in 2018 by Kelsey Mellard, Shaun Lindsay, and Sohrab Gollogly.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Senti Biosciences is a biotechnology company focused on synthetic biology and gene circuit engineering for therapeutic applications. Senti Bio utilizes a synthetic biology platform named Gene Circuits to develop therapies that offer improved precision and control. These circuits are engineered to selectively eliminate cancer cells while sparing healthy ones, enhancing specificity for target cells, and regulating drug expression post-administration.
Floreo is a virtual reality therapy system for autism, ADHD and anxiety therapy. Floreo is now used by over 100 therapy clinic businesses and school districts. We're a trail blazer for digital therapeutic reimbursement as the first VR behavioral health company w/ an approved CPT 3 reimbursement code. And we're partnered with Meta to help bring Floreo VR to public schools.
Notable Labs is a personalized testing service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor without a clinical trial.
Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.
Clover Health is a provider of Medicare Advantage health plans to older Americans. The company operates a Preferred Provider Organization (PPO) platform to improve the quality of life of its members and physicians. Its platform utilizes patient-centered analytics and a dedicated care management team to identify potential risks and directly provide preventive care, thereby enabling patients and their health care providers to reduce avoidable spending as well as identify and manage chronic diseases. Clover uses sophisticated analytics and custom software to direct its own clinical staff to proactively fill in gaps in the care of its members.
Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diverse macrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diverse macrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp.
Advantia Health is dedicated to helping women manage their health and the health of their families. Advantia Health is an integrated healthcare delivery company that helps women manage their health and the health of their families. The company provides high quality, high-value care using technology, and highly efficient outpatient facilities. It was founded in 2014 and is headquartered in Arlington, Virginia.
dr.consulta is a healthcare company in Brazil. We begun as a full stack primary care provider and evolved to become a HMO. Our target audience are uninsured individuals.
Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.
Included Health provides a combination of virtual care, navigation, and communities-based healthcare services. Included Health combines people and technology to guide and deliver care differently. Its model is designed to treat people better. The company offers care guidance, advocacy, and access to personalized virtual and in-person care for everyday and urgent care, primary care, behavioral health, and specialty care.
Aspire Health is a new healthcare company that specializes in providing an extra layer of support to patients facing a serious illness. The company's clinicians are experts in providing patients with relief from the symptoms, pain, and stress of a serious illness, helping patients and caregivers navigate the healthcare system; guiding patients and caregivers through difficult and complex treatment choices, and providing emotional and spiritual support to patients and their families. The company's practice in each market provides disease management and care coordination across many settings including outpatient clinics, patients’ homes, and assisted living centers. It was established in 2012 and is based in Nashville, Tennessee, United States.
Private Equity Round in 2014
Amazon One Medical is a members-only technology platform offering an array of concierge medical services. The integration of these elements allows a seamless experience that not only saves the patients time and money but also leads to better health outcomes and happier lives. The company attracts the highest caliber team of healthcare providers, allowing them to practice medicine the way it should be. It makes access to care frictionless with face-to-face virtual video visits available anytime. It allows practicing medicine the way it should be practiced, focusing on improving the patient experience and challenging the healthcare status quo.
HeartFlow focuses on precision heart care, combining human ingenuity with technology. HeartFlow’s non-invasive HeartFlow FFRCT Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage has on blood flow and determine the best treatment for patients. HeartFlow’s technology is reflective of our Silicon Valley roots and incorporates over two decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRCT Analysis is commercially available in the United States, UK, Canada, Europe, and Japan.
Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.